▎ 摘　　要

NOVELTY - Method (A) for assessing likelihood of developing Alzheimer's disease, determining Alzheimer's disease or monitoring Alzheimer's disease progression in a subject involves (a) determining presence and/or amount of one or more protein biomarkers in the subject or biofluid taken from the subject. USE - The method (A) is useful for assessing likelihood of developing Alzheimer's disease, determining Alzheimer's disease, or monitoring Alzheimer's disease progression in subject. The subject is a human (claimed). ADVANTAGE - None given. DETAILED DESCRIPTION - Method (A) for assessing likelihood of developing Alzheimer's disease, determining Alzheimer's disease or monitoring Alzheimer's disease progression in a subject involves (a) determining presence and/or amount of one or more protein biomarkers in the subject or biofluid taken from the subject. The protein biomarker is chosen from (i) protein biomarkers mentioned in table 6a of patent specification, including angiopoietin-like 6 isoform CRA-a, anoctamin (fragment), apolipoprotein E (fragment), leukocyte surface antigen CD53, proteoglycan 4 isoform CRA-a, transmembrane protein 163 (TMEM163), ankyrin repeat domain-containing protein 61, apolipoprotein A-I isoform CRA-a (APOA1), APOA2, apolipoprotein A-IV, APOC3, apolipoprotein D, fermitin family homolog 3 (FERMT3), glutathione peroxidase, hyaluronan-binding protein 2, epididymis luminal protein 180, immunoglobulin heavy variable 3-38, prenylcysteine oxidase 1, phospholipid transfer protein, serum paraoxonase/aryl esterase 1, serum paraoxonase/lactonase 3, selenoprotein P, α -1-antitrypsin, and tissue factor pathway inhibitor, (ii) protein biomarkers mentioned in table 1 of patent specification, including 14-3-3 protein zeta/δ , 26S proteasome non-ATPase regulatory subunit 1, 26S proteasome non-ATPase regulatory subunit 14, 26S proteasome non-ATPase regulatory subunit 2, 26S proteasome non-ATPase regulatory subunit 3, 26S proteasome non-ATPase regulatory subunit 6 (fragment), 26S proteasome regulatory subunit 10B, 26S proteasome regulatory subunit 6A (fragment), 40S ribosomal protein S9, 55 kDa erythrocyte membrane protein, 60S ribosomal protein L18, 60S ribosomal protein L6, acylamino-acid-releasing enzyme, adenylyl cyclase-associated protein 1, adiponectin, ADP/ATP translocase 2, α -actinin 1, aminopeptidase N, angiopoietin-1, ankyrin-1, annexin A2, annexin A5, annexin A6, anti-colorectal carcinoma light chain, CD5 antigen-like, CD9 antigen, clathrin heavy chain 1, clusterin, dihydrolipoyl lysine-residue succinyl transferase component of 2-oxoglutarate dehydrogenase complex, fibronectin, filamin-A, filamin-B, immunoglobulin heavy variable 1-52, immunoglobulin heavy variable 1-69, integrin α -2b, integrin β , integrin β -1, integrin β -3, vimentin and vinculin, or (iii) protein biomarkers mentioned in table 1a of patent specification, including anoctamin, apolipoprotein E, superoxide dismutase, uncharacterized protein, pyruvate kinase, hepatocyte growth factor activator, plasma kallikrein, catalase, transmembrane protein 163, histone, coagulation factor XI, transcobalamin-1, corticosteroid-binding globulin, apolipoprotein D, Kelch-like protein 34, serum albumin, C-reactive protein, serum amyloid A, coiled-coil domain-containing protein 40, immunoglobulin heavy variable 3-9, tenascin-X, apolipoprotein M, semenogelin-1, ceruloplasmin, angiotensinogen, α -1-acid glycoprotein 2 and testicular tissue protein. INDEPENDENT CLAIMS are included for the following: a method (B) for testing a patient's biofluid sample for one or more biomarkers of Alzheimer's disease; a method (C) for monitoring Alzheimer's disease (AD) progression in a subject; a method (D) for assessing the stage of AD in a subject; a method (E) for assessing stage of AD in a subject; and a method (F) for identifying neurodegeneration-associated protein biomarkers in the blood of a subject.